HSP90AA1 and hepatocellular carcinoma: While the efficacy of inhibitors targeting the other Hsp90 protein, such as Ganetespib (STA-9090) and luminespib (AUY922), has been demonstrated in certain cancers, including hepatocellular carcinoma (HCC) (192), pancreatic cancer (PC) (193), gastric cancer (GC) (194, 195).